FINAL PROGRAM - Imo

Original Papers
pected retinoblastoma between 1974 and 2011, 2171 patients (78%) had
retinoblastoma and 604 patients (22%) had simulating lesions. Of these 604
patients, there were 27 different etiologies. The 3 most common conditions
were Coats disease (244, 40%), persistent fetal vasculature (PFV) (158, 28%),
and vitreous hemorrhage (27, 5%). The remainder of the patients had less
common simulating conditions. Conclusion: Coats disease, PFV, and vitreous
hemorrhage are the most common simulators of retinoblastoma.
3:31 PM
Panel discussion of previous paper
Part II, 3:42 PM - 5:35 PM
Moderator: John T Thompson MD
Panel: Dean Eliott MD, Harry W Flynn Jr MD, K Bailey Freund MD
PA056
3:42 PM
Combining Genotype and Phenotype to Predict Progression
to Choroidal Neovascularization
Presenting Author: Lorah Perlee*
Co-Author(s): Aruna T Bansal PhD*, Karen Marie Gehrs MD*, Jeffrey S
Heier MD*, Karl G Csaky MD*, Rando Allikmets PhD**, Paul Oeth MS**,
Toni Paladino PhD*, Daniel H Farkas PHD*, Lyle Rawlings*, Gregory S
Hageman PhD*
Purpose: Accuracy of prediction of CNV development was evaluated in
patients with AMD using a model that combined baseline disease severity
and genetic burden. Methods: An analysis was performed on 2414 AREDS
subjects graded at baseline (AREDS simplified severity scale), surveyed
across 13 disease-associated genetic variants and evaluated based on 10-
year follow-up data. Results: Allowing for variation in baseline grade, the
median predicted probability of progression was 0.2% (range: 0.04%-12%) in
subjects with the lowest genetic load, compared to 57% (range: 26%-99%)
in subjects with the highest genetic load. Conclusion: Evaluating patient
genotype in combination with baseline disease improves the accuracy of CNV
prediction.
3:49 PM
Panel discussion of previous paper
PA057
3:54 PM
Integrated 96-Week Results From the VIEW 1 & VIEW 2
Studies: Intravitreal Aflibercept Injection in Neovascular
AMD
Presenting Author: Peter K Kaiser MD*
On behalf of VIEW1 and VIEW2 Investigators
Purpose: To assess efficacy and safety of intravitreal aflibercept (IAI) vs.
ranibizumab (RBZ). Methods: Patients were randomized to RBZ 0.5 mg
monthly (Rq4); IAI 2 mg monthly (2q4), 0.5 mg monthly (0.5q4), or 2 mg every
2 months (2q8) after 3 loading doses. Weeks 52 to 96 patients were treated
with modified quarterly dosing. Results: At Week 96, visual acuity (VA) gains
were 7.9, 7.6, 6.6, and 7.6 letters, respectively. Most frequent ocular adverse
events were conjunctival hemorrhage, eye pain, retinal hemorrhage, and VA
reduced. Conclusion: VA improvements with IAI and RBZ at Week 52 were
largely maintained through Week 96; efficacy of 2q8 IAI was similar to Rq4.
4:01 PM
Panel discussion of previous paper
PA058
4:06 PM
Anatomic Correlates of Long-term Visual Outcomes in the
ANCHOR/MARINA Cohort of Ranibizumab-Treated AMD
Patients
Presenting Author: Soraya Rofagha MD
Co-Author(s): Robert B Bhisitkul MD**, David S Boyer MD*, Kang Zhang MD
PhD*, Srinivas R Sadda MD*
Purpose: To report long-term visual and anatomic outcomes of ranibizumabtreated
exudative AMD patients from the ANCHOR/MARINA trials with carryover
into the HORIZON trial. Methods: Multicenter, uncontrolled, crosssectional
study. Patients were evaluated with ETDRS visual acuity, biomicroscopy,
retinal imaging, and genetic analysis. Results: Fifteen sites recruited
65 patients with average follow-up of 7.3 years. Thirty-seven percent of eyes
were 20/70 or better. On average, eyes lost 8.6 and 19.8 letters since entry
and exit from MARINA/ANCHOR, respectively; 67% had CNV on fluorescein
angiography (FA) and 68% had cystoid macular edema and/or SRF on OCT.
Conclusion: A minority of eyes had good visual and anatomic outcomes.
Most eyes were active by FA and OCT; visual correlates suggest that close
follow-up and therapeutic vigilance is necessary.
4:13 PM
Panel discussion of previous paper
APAO PA059
4:18 PM
Comparison of Ranibizumab (Lucentis) and Photodynamic
Therapy on Polypoidal Choroidal Vasculopathy (LAPTOP)
Study
Presenting Author: Akio Oishi MD PHD
Co-Author(s): Hiroshi Kojima MD PhD, Michiko Mandai*, Shigeru Honda
MD PHD, Toshiyuki Matsuoka MD PhD, Hideyasu Oh MD PHD, Mihori Kita,
Tomoko Nagai MD, Masashi Fujihara MD PhD, Masafumi Uematsu MD,
Yasuo Kurimoto MD PhD*, Akira Negi MD
Purpose: To compare visual outcome between intravitreal injection of ranibizumab
(IVR) and photodynamic therapy (PDT) in patients with polypoidal
choroidal vasculopathy (PCV). Methods: We randomly assigned 94 patients
with PCV to IVR or PDT. After 1 year of treatment protocol, the rate of visual
acuity improvement or worsening as judged by 0.2 logMAR units change was
compared. Results: After the exclusion of 6 patients who had dropped out,
IVR and PDT groups consisted of 44 and 44 patients, respectively. Visual outcome
was superior in IVR (improved: unchanged: worsened = 27%:66%:7%
in IVR group and 16%:59%:25% in PDT group, P = .046). Conclusion: In
PCV patients, IVR retained visual acuity better than PDT after 1 year of each
treatment option.
4:25 PM
Panel discussion of previous paper
PA060
4:30 PM
The Mahalo Phase 1b Study: Multidose Safety and
Tolerability of FCFD4514S (Antifactor D) in Geographic
Atrophy
Presenting Author: David F Williams MD*
Co-Author(s): Erich C Strauss MD*, Michel Friesenhahn MD*, Alice Fong
PharmD*
Purpose: The Phase 1b safety run-in portion of the Mahalo study evaluated
safety and tolerability of multiple monthly doses of a novel antibody fragment
(FCFD4514S) in geographic atrophy patients prior to initiating the Mahalo
Phase 2 study. Methods: Patients received a minimum of 3 monthly 10-mg
Original Papers
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date.
No asterisk indicates that the presenter has no financial interest.
Up-to-date information is available in the Program Search on the Academy’s website: www.aao.org/2012.
171